Ekso Bionics Hlds

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ekso Bionics reports record sales and margin growth in Q2 2024

Ekso Bionics delivered a strong performance in Q2 2024 with record sales, improved gross margins, and effective cost management.
The company's focus on expanding relationships, receiving Medicare reimbursement, and collaborations in neurorehabilitation centers position it well for growth.
While facing challenges in competitive industrial segments and margin sustainability, Ekso Bionics has opportunities to leverage international demand and market expansion.

Ekso Bionics reports solid Q3 performance, eyes global expansion

Ekso Bionics demonstrated solid performance in Q3 2024 with improved operational efficiency and strong international sales, despite challenges in the U.S. market.
The company's focus on market education, product reimbursement, and cost management positions it well for future growth and market expansion.
While facing challenges in achieving profitability and managing U.S. sales fluctuations, Ekso Bionics has opportunities to capitalize on its strengths and drive further growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q2 2021 Results - Earnings Call Transcript

RICHMOND, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2021.

Ekso Bionics Reports Second Quarter 2021 Results

Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Ekso Bionics (EKSO) Report Negative Q2 Earnings? What You Should Know

Ekso Bionics (EKSO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Ekso Bionics (EKSO)

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q1 2021 Results - Earnings Call Transcript

Shares of Ekso Bionics Holdings (NASDAQ:EKSO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 22.73% year over year to ($0.34), which missed the estimate of ($0.24).

Ekso Bionics Holdings: Q1 Earnings Insights

RICHMOND, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2021.

Ekso Bionics Reports First Quarter 2021 Results

Will Ekso Bionics (EKSO) Report Negative Q1 Earnings? What You Should Know

RICHMOND, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2021 after the close of trading on Thursday, April 29, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report First Quarter 2021 Financial Results on April 29, 2021

Ekso Bionics (EKSO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ekso Bionics (EKSO) Surges 9.4%: Is This an Indication of Further Gains?

RICHMOND, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced a partnership with U.S. Physiatry (USP) to educate physicians on the clinical benefits of an EksoNR exoskeleton. USP is the largest inpatient physician practice in the U.S. focused exclusively on physical medicine and rehabilitation. The partnership will help expand awareness of Ekso Bionics' technology among physicians and other rehabilitation clinicians as well as educate on how to successfully implement robotics into a rehabilitation program.

Ekso Bionics Announces Partnership with U.S. Physiatry to Support Physician Education of EksoNR

Ekso Bionics' (EKSO) CEO Jack Peurach on Q4 2020 Results - Earnings Call Transcript

Shares of Ekso Bionics Holdings (NASDAQ:EKSO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 1100.00% over the past year to ($0.48), which missed the estimate of ($0.30).

Recap: Ekso Bionics Holdings Q4 Earnings

On Thursday, February 25, Ekso Bionics Holdings (NASDAQ:EKSO) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview: Ekso Bionics Holdings

RICHMOND, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2020 after the close of trading on Thursday, February 25, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics® to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

RICHMOND, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions. As previously announced, Ekso Bionics also has granted to the underwriter a 30-day option to purchase up to an additional 585,366 shares of common stock at the public offering price, less underwriting discounts and commissions.

Ekso Bionics Announces Closing of $40 Million Bought Deal Offering

Ekso Bionics Holdings Inc (NASDAQ: EKSO) has increased the size of the previously announced public offering to 3.9 million common shares at $10.25 per share, raising around $40 million in gross proceeds from the previous offer of 975,610 shares for $10 million. The offer price is at a 28% discount on the last close price of $13.07 on Monday.

Ekso Bionics Raises $40M From Upsized Equity Offering At 28% Discount, Shares Tank

RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions.

Ekso Bionics Increases Previously Announced Bought Deal Offering of Common Stock to $40 Million

RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 975,610 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions.

Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock

ReWalk Robotics

Science fiction collides with reality, as exoskeletons become a real-world device with a number of applications. The post 2 Science-Fiction Stocks to Play This Emerging Megatrend appeared first on InvestorPlace.

2 Science-Fiction Stocks to Play This Emerging Megatrend

RICHMOND, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2020.

Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2020 Financial Results

RICHMOND, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors by vote of stockholders at its 2020 Annual Meeting on December 29, 2020, effective immediately.

Ekso Bionics' Stockholders Elect Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors

In this article you are going to find out whether hedge funds think Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It's not surprising given that hedge funds have access to better information and more resources to predict the winners in the stock market.

Is Ekso Bionics Holdings, Inc. (EKSO) A Good Stock To Buy Now?

RICHMOND, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the continued adoption of its latest industry exoskeleton innovation, EVO, with a subscription-based order by Cloverdale Foods Company, a fourth generation, family-owned meat company.

Ekso Bionics Announces Continued Adoption of EVO™ with Flexible Subscription-Based Order from Cloverdale Foods Company

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q3 2020 Results - Earnings Call Transcript

News for Ekso Bionics Hlds Stock (EKSO)